Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.

Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.

OBJECTIVE To determine whether use of the injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera) affects the risk of breast cancer in women. DESIGN A population based case-control study. SETTING Nationwide community study. SUBJECTS 891 Women aged 25-54 with newly diagnosed breast cancer were compared with 1864 women selected at random from the electoral rolls. INTERVE...

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery

In the US, obesity rates are increasing greatly. The Centers for Disease Control and Prevention estimates that 68.5% of Americans, including 63.9% of adult women older than 20 years, are overweight (body mass index between 25 kg/m2 and 29.9 kg/m2) or obese (body mass index >30 kg/m2). In light of this, it is not surprising that the rates of bariatric surgery have also been increasing. When cons...

Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss.

Medroxyprogesterone acetate [Depo Provera] injections. Development of striae.

A young girl developed extensive striae while on Depo Provera injections. She had gained some weight during the treatment. Endocrinal investigations were negative. The development of striae was attributed to her weight gain.

Treatment of sex offenders with Depo-Provera.

Medroxyprogesterone acetate (MPA) is capable of reducing male testosterone blood levels with a corresponding reduction in sexual interest and activity. An attempt to evaluate its effectiveness with court committed sexual offenders was made with eight subjects each serving as his own control by alternating Depo-Provera injections for 16 weeks with saline injections for a corresponding 16 weeks. ...